Angelalign finds new smile in central procurement era
Despite swallowing lower prices under a government procurement program, the leading ‘invisible’ dental braces maker posted strong profit and revenue gains in the first half of 2026 Key Takeaways: Angelalign’s…
PrimeGenX looks to a Hong Kong IPO as a cure for its cash woes
The developer of anti-inflammatory treatments will need to persuade investors to look past its balance sheet problems and its narrow pipeline of products Key Takeaways: The company is making a…
Traditional Chinese medicine leader Yuyantang finds tonic in aging population
The company has filed for a Hong Kong IPO, thriving on China’s growing silver economy and a steady stream of government policies supporting traditional Chinese medicine Key Takeaways: Yuyantang has…
Cold-chain provider Shanghai Shengsheng joins pharma IPO hopefuls
China’s biggest supplier of temperature-controlled services for the drug sector has renewed a Hong Kong listing plan, raising questions with hefty pre-IPO payouts Key Takeaways: Turnover has grown steadily, driven…
Biokin’s world-first bispecific ADC hits milestones, speeding commercialization
Iza-bren was approved for recurrent or metastatic esophageal squamous cell carcinoma, after receiving earlier approval to treat nasopharyngeal carcinoma Key Takeaways: New approvals for Biokin’s Iza-bren highlight the rise of…
MicroPort MedBot serves up inaugural profit on booming exports
The medical robot maker expects to report a profit of 28 million yuan to 40 million yuan for the first half of 2026, reversing years of losses Key Takeaways: MicroPort…
Joinn’s profit figures spark market outbreak of “monkey fever”
Projected earnings at the drug research company have been inflated by the soaring value of research monkeys, but the on-paper gains may not be sustainable Key Takeaways: Joinn Laboratories uses…